Adaptive Biotechnologies Corporation (ADPT) dividends
ADPT on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Adaptive Biotechnologies Corporation dividend: key facts
Own Adaptive Biotechnologies Corporation? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next ADPT dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Adaptive Biotechnologies price target raised to $35 from $27 at Piper Sandler11 Nov 2026 · TheFly
Piper Sandler raised the firmâs price target on Adaptive Biotechnologies (ADPT) to $35 from $27 and keeps an Overweight rating on the shares. The firm is updating its estimates andâ¦
- Adaptive Biotechnologies price target raised to $34 from $32 at Guggenheim11 Nov 2026 · TheFly
Guggenheim raised the firmâs price target on Adaptive Biotechnologies (ADPT) to $34 from $32 and keeps a Buy rating on the shares.
- Adaptive Biotechnologies to Participate in Upcoming Investor Conferences11 Nov 2026 · GlobeNewsWire
SEATTLE, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (âAdaptive Biotechnologiesâ) (Nasdaq: ADPT),), a commercial stage biotechnology company that aims to translate the gene...
- Adaptive Biotechnologies price target raised to $35 from $30 at JPMorgan9 Nov 2026 · TheFly
JPMorgan analyst Casey Woodring raised the firmâs price target on Adaptive Biotechnologies (ADPT) to $35 from $30 and keeps an Overweight rating on the shares.
- Adaptive Biotechnologies reports Q3 EPS 2c, consensus (10c)5 Nov 2026 · TheFly
Reports Q3 revenue $83.9M, consensus $71.6M. Core MRD revenue increased 28% year-over-year to $72.6M, while clonoSEQ test volume grew 46% to 39,587 tests. âAdaptive achieved total company profitabilit...
- Adaptive Biotechnologies raises FY26 revenue view to $276M-$286M5 Nov 2026 · TheFly
Prior guidance for FY26 revenue was from $268M-$278M. Consensus for FY26 total revenue is $293.25M. The company raised its full-year MRD business outlook, representing annual growth of 30% to 35%,â¦
- Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results5 Nov 2026 · GlobeNewsWire
SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Â Adaptive Biotechnologies Corporation (âAdaptive Biotechnologiesâ) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the geneti...
- Adaptive Biotechnologies price target raised to $32 from $28 at TD Cowen17 Oct 2026 · TheFly
TD Cowen raised the firmâs price target on Adaptive Biotechnologies (ADPT) to $32 from $28 and keeps a Buy rating on the shares. The firm adjusted targets in the diagnosticsâ¦
Insufficient verified data for a financial-health score
Dividend data and price last updated 18 Nov 2026.